Cargando…
1982. GLP-1 Receptor Agonists Promote Weight Loss Among People with HIV
BACKGROUND: Weight gain and associated metabolic complications are increasingly prevalent among people with HIV (PWH), especially those initiating second-generation integrase strand transfer inhibitors (INSTIs). Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are incretin-based therapies for d...
Autores principales: | Nguyen, Quynh P, Wooten, Darcy, Duren, Kye, Moreno, Manuel, Promer, Katherine, Hien Tan, Matthew, Tang, Michael E, Rajagopal, Amutha V, Hill, Lucas, Yin, Jeffrey, Toperoff, Will |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679091/ http://dx.doi.org/10.1093/ofid/ofad500.109 |
Ejemplares similares
-
GLP-1 Receptor Agonists: Nonglycemic Clinical Effects in Weight Loss and Beyond
por: Ryan, Donna, et al.
Publicado: (2015) -
443. Do people living with HIV lose weight on GLP-1 agonist therapy?
por: Tauhid, Lamiya, et al.
Publicado: (2022) -
COVID-19 Telemedicine and Vaccination at an Urban Safety Net HIV Medicine Clinic
por: Anson, Ryan, et al.
Publicado: (2022) -
Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss
por: Iepsen, E W, et al.
Publicado: (2015) -
Treatment with GLP-1 receptor agonists is associated with significant weight loss and favorable headache outcomes in idiopathic intracranial hypertension
por: Krajnc, Nik, et al.
Publicado: (2023)